Applying New Dyslipidemia Guidelines in Pharmacy Practice

New clinical guidelines for the management of dyslipidemia are shifting the role of pharmacists toward more aggressive early risk assessment and the expanded use of combination therapies to reduce cardiovascular risk.

According to reports from Pharmacy Times, these updates emphasize the importance of implementing ApoB testing and utilizing the PREVENT ASCVD calculator, which serves as an improvement over previous risk assessment tools.

Updates to Risk Assessment and Testing

A central component of the updated approach involves the integration of ApoB testing. Pharmacists are encouraged to apply these guidelines to identify patients who may require more intensive lipid-lowering interventions.

The transition to the PREVENT ASCVD calculator represents a significant update in how clinicians determine a patient’s risk of atherosclerotic cardiovascular disease. Joseph Saseen, PharmD, has noted that this tool improves upon its predecessor in assessing patient risk.

These changes are designed to facilitate earlier risk assessment, allowing for medical intervention before cardiovascular events occur.

Expanded Treatment Goals and Therapies

The guidelines include expanded LDL-C goals, reflecting a move toward more stringent targets for specific patient populations to better manage cardiovascular health.

There is also an increased focus on the use of combination lipid-lowering therapy. By utilizing multiple agents simultaneously, clinicians aim to achieve target lipid levels more effectively than with monotherapy alone.

These pharmacological updates are part of a broader effort to refine how dyslipidemia is managed in adult populations, emphasizing patient-important outcomes.

The 2025 AACE Clinical Practice Guidelines

Parallel to these developments, the American Association of Clinical Endocrinology (AACE) released the 2025 Clinical Practice Guideline for the Pharmacologic Management of Adults with Dyslipidemia.

Developed by a multidisciplinary task force using the GRADE framework, the AACE guidelines provide evidence-based recommendations on the benefits and harms of newer medications.

The 2025 AACE update focuses on several key areas:

• Differences in recommendations compared to the 2017 guideline.
• Integration of evidence assessments to shape treatment goals.
• Guidance for clinicians on integrating updated recommendations into daily practice.
• Identification of existing gaps in literature and opportunities for future research.

Implementation in Pharmacy Practice

Pharmacists are positioned to play a central role in the implementation of these guidelines. Their involvement includes managing the transition to new calculators and coordinating the expanded use of combination therapies.

The updated frameworks aim to improve shared decision-making between providers and patients, particularly through the use of patient-friendly summaries that explain options for reducing lipids and heart disease risk.

As of April 2026, these updated lipid management strategies continue to generate significant discussion among clinicians as they integrate the new standards into clinical workflows.